Key facts

Invented name
  • Menveo
  • Menveo
Active Substance
Meningococcal group A oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenA-CRM) Meningococcal group C oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenC-CRM) Meningococcal group W-135 oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenW-CRM) Meningococcal group Y oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenY-CRM)
Therapeutic area
Vaccines
Decision number
P/93/2011
PIP number
EMEA-000032-PIP01-07-M04
Pharmaceutical form(s)
Powder and solvent for solution for injection
Condition(s) / indication(s)
Meningococcal meningitis
Route(s) of administration
Intramuscular use
Contact for public enquiries

GSK Vaccines S.r.l.

Tel. +1 438 899 8201
Email: eu.paediatric-plans@gsk.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance procedure number
EMEA-C-000032-PIP01-07-M04
Compliance opinion date
Compliance outcome
Positive

Decision

How useful do you find this page?